Arginase-1 (D4E3M™) XP® Rabbit mAb recognizes endogenous levels of total arginase-1 protein. This antibody does not cross-react with arginase-2.
Species Reactivity: Human, Mouse, Rat
Application
Dilutions
Western Blotting
1:1000
IHC-Leica® Bond™
1:400
Immunohistochemistry (Paraffin)
1:100
Immunofluorescence (Frozen)
1:50
Immunofluorescence (Immunocytochemistry)
1:50
Storage:
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
Background:
L-arginine plays a critical role in regulating the immune system (1-3). In inflammation, cancer and certain other pathological conditions, myeloid cell differentiation is inhibited leading to a heterogeneous population of immature myeloid cells, known as myeloid-derived suppressor cells (MDSCs). MDSCs are recruited to sites of cancer-associated inflammation and express high levels of arginase-1 (4). Arginase-1 catalyzes the final step of the urea cycle converting L-arginine to L-ornithine and urea (5). Thus MDSCs increase the catabolism of L-arginine resulting in L-arginine depletion in the inflammatory microenvironment of cancer (4, 6). The reduced availability of L-arginine suppresses T-cell proliferation and function and thus contributes to tumor progression (4, 6). Arginase-1 is of great interest to researchers looking for a therapeutic target to inhibit the function of MDSCs in the context of cancer immunotherapy (7). In addition, research studies have demonstrated that Arginase-1 distinguishes primary hepatocellular carcinoma (HCC) from metastatic tumors in the liver, indicating its value as a potential biomarker in the diagnosis of HCC (8, 9).